Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price rose 4.4% on Wednesday . The company traded as high as $6.82 and last traded at $6.60. Approximately 5,031,041 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 15,167,364 shares. The stock had previously closed at $6.32.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on RXRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp reduced their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.75.
Check Out Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Up 1.6 %
The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $2.51 billion, a P/E ratio of -4.20 and a beta of 0.85. The firm's 50-day moving average price is $6.93 and its 200 day moving average price is $6.97.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.43) EPS. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the sale, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at $3,288,380.78. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,894 shares of company stock worth $317,139. Corporate insiders own 15.75% of the company's stock.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Several large investors have recently bought and sold shares of RXRX. Arkadios Wealth Advisors acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $84,000. Avanza Fonder AB acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $580,000. Decker Retirement Planning Inc. bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $26,000. 180 Wealth Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 21.2% in the fourth quarter. 180 Wealth Advisors LLC now owns 31,230 shares of the company's stock valued at $211,000 after purchasing an additional 5,455 shares in the last quarter. Finally, Wedmont Private Capital lifted its position in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock worth $144,000 after purchasing an additional 2,000 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
